TR201909277T4 - Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları. - Google Patents
Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları. Download PDFInfo
- Publication number
- TR201909277T4 TR201909277T4 TR2019/09277T TR201909277T TR201909277T4 TR 201909277 T4 TR201909277 T4 TR 201909277T4 TR 2019/09277 T TR2019/09277 T TR 2019/09277T TR 201909277 T TR201909277 T TR 201909277T TR 201909277 T4 TR201909277 T4 TR 201909277T4
- Authority
- TR
- Turkey
- Prior art keywords
- rasagiline
- extended release
- release formulations
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 title abstract 2
- 229960000245 rasagiline Drugs 0.000 title abstract 2
- 238000013265 extended release Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000001738 Nervous System Trauma Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- RUOKEQAAGRXIBM-UHFFFAOYSA-N n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2C(NCC#C)CCC2=C1 RUOKEQAAGRXIBM-UHFFFAOYSA-N 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30101910P | 2010-02-03 | 2010-02-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201909277T4 true TR201909277T4 (tr) | 2019-07-22 |
Family
ID=43896855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/09277T TR201909277T4 (tr) | 2010-02-03 | 2011-02-03 | Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9943489B2 (enExample) |
| EP (2) | EP2531181B1 (enExample) |
| JP (3) | JP6045347B2 (enExample) |
| KR (1) | KR101791715B1 (enExample) |
| CN (1) | CN102791258B (enExample) |
| AU (1) | AU2011212068B2 (enExample) |
| BR (1) | BR112012019374B1 (enExample) |
| CA (1) | CA2789006C (enExample) |
| CL (1) | CL2012002175A1 (enExample) |
| CY (1) | CY1121781T1 (enExample) |
| DK (1) | DK2531181T3 (enExample) |
| ES (1) | ES2733133T3 (enExample) |
| HU (1) | HUE044221T2 (enExample) |
| IL (1) | IL221274A (enExample) |
| LT (1) | LT2531181T (enExample) |
| MX (1) | MX354423B (enExample) |
| NZ (1) | NZ602111A (enExample) |
| PL (1) | PL2531181T3 (enExample) |
| PT (1) | PT2531181T (enExample) |
| RS (1) | RS58988B1 (enExample) |
| RU (2) | RU2734632C2 (enExample) |
| SG (1) | SG183150A1 (enExample) |
| TR (1) | TR201909277T4 (enExample) |
| WO (1) | WO2011095973A1 (enExample) |
| ZA (1) | ZA201206462B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101791715B1 (ko) * | 2010-02-03 | 2017-10-30 | 파마 투 비 엘티디 | 라사길린의 연장 방출 제형 및 그 용도 |
| CA2758556A1 (en) * | 2011-11-17 | 2013-05-17 | Pharmascience Inc. | Pharmaceutical composition of amphetamine mixed salts |
| US20150079187A1 (en) * | 2012-01-12 | 2015-03-19 | Pharma Two B Ltd. | Fixed dose combination therapy of parkinson's disease |
| US9504657B2 (en) * | 2012-01-12 | 2016-11-29 | Pharmatwob Ltd. | Fixed dose combination therapy of Parkinson's disease |
| CN102579367B (zh) * | 2012-03-23 | 2014-03-12 | 中国人民解放军军事医学科学院毒物药物研究所 | 托吡酯缓释药物组合物、其制备方法及用途 |
| CN103316026B (zh) | 2012-03-23 | 2016-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 含芬特明和托吡酯的联合产品及其制备方法 |
| US9457008B2 (en) | 2012-03-23 | 2016-10-04 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China | Joint product comprising synephrine and topiramate |
| AR092168A1 (es) | 2012-08-17 | 2015-03-25 | Teva Pharma | Formulaciones parenterales de rasagilina |
| IN2013MU01782A (enExample) * | 2013-05-20 | 2015-06-26 | Cadila Healthcare Ltd | |
| US20150275167A1 (en) * | 2014-03-28 | 2015-10-01 | Corning Incorporated | Composition and method for cell culture sustained release |
| KR102804202B1 (ko) | 2014-09-15 | 2025-05-12 | 제브라 덴마크 에이/에스 | 아리모클로몰 제제 |
| CA3064006C (en) * | 2017-05-19 | 2025-09-16 | Biscayne Neurotherapeutics Inc | Modified release pharmaceutical compositions of huperzine and methods of using the same |
| CN107049985B (zh) * | 2017-06-07 | 2020-06-19 | 广州帝奇医药技术有限公司 | 一种抗帕金森病药物的长效缓释制剂及其制备方法 |
| US11717501B2 (en) * | 2018-04-25 | 2023-08-08 | Neurocentria, Inc. | Magnesium threonate compositions and uses thereof |
| KR20220015437A (ko) * | 2019-05-31 | 2022-02-08 | 데날리 테라퓨틱스 인크. | 피리미디닐아미노-피라졸 화합물의 변형 방출 제제, 및 치료 방법 |
| KR20210014289A (ko) | 2019-07-30 | 2021-02-09 | (주)비씨월드제약 | 라사길린을 함유하는 서방출성 미립구의 제조방법 |
| AR121619A1 (es) * | 2020-03-25 | 2022-06-22 | Inibsa Ginecologia S A | Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación |
| WO2022238401A1 (en) * | 2021-05-11 | 2022-11-17 | Advicenne | Prolonged-release pharmaceutical composition for oral administration of sultiame |
| CN118680910B (zh) * | 2024-08-26 | 2024-12-03 | 山东齐都药业有限公司 | 用于缓释递送雷沙吉兰甲磺酸盐的药物组合物及其制备方法和应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4415547A (en) * | 1982-06-14 | 1983-11-15 | Sterling Drug Inc. | Sustained-release pharmaceutical tablet and process for preparation thereof |
| US4861800A (en) | 1987-08-18 | 1989-08-29 | Buyske Donald A | Method for administering the drug deprenyl so as to minimize the danger of side effects |
| HU208484B (en) | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
| IL92952A (en) * | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| US5225446A (en) | 1990-08-31 | 1993-07-06 | Deprenyl Animal Health, Inc. | Use of 1-deprenyl for retention of specific physiological functions |
| CA2039194C (en) | 1990-08-31 | 1997-01-28 | Norton W. Milgram | Uses of l-deprenyl and compositions for same |
| US5151449A (en) | 1990-08-31 | 1992-09-29 | Deprenyl Animal Health, Inc. | Use of L-deprenyl for retention of specific physiological functions |
| US5192808A (en) | 1990-08-31 | 1993-03-09 | Deprenyl Animal Health, Inc. | Therapeutic effect of L-deprenyl in the management of pituitary-dependent hyperadrenocorticism (cushing's disease) |
| US5169868A (en) | 1991-03-01 | 1992-12-08 | University Of Saskatchewan | Aliphatic propargylamines as specific mao-b inhibitors |
| WO1992017169A1 (en) | 1991-04-04 | 1992-10-15 | The University Of Toronto Innovations Foundation | Use of deprenyl to maintain, prevent loss, or recover nerve cell function |
| WO1992021333A2 (en) | 1991-05-24 | 1992-12-10 | Pharmavene, Inc. | Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors |
| IL99759A (en) | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
| US5242950A (en) | 1992-04-23 | 1993-09-07 | Somerset Pharmaceuticals, Inc. | Treatment of macular degeneration |
| JP2916978B2 (ja) * | 1993-08-25 | 1999-07-05 | エスエス製薬株式会社 | 放出開始制御型製剤 |
| IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
| US6348208B1 (en) | 1995-01-13 | 2002-02-19 | Somerset Pharmaceuticals, Inc. | Methods and pharmaceutical compositions employing desmethylselegiline |
| PE57198A1 (es) * | 1996-03-25 | 1998-10-10 | American Home Prod | Formula de liberacion prolongada |
| IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| US6251938B1 (en) | 1996-12-18 | 2001-06-26 | Teva Pharmaceutical Industries, Ltd., | Phenylethylamine derivatives |
| HU229507B1 (en) | 1996-12-18 | 2014-01-28 | Technion Res & Dev Foundation | 1,2,3,4-tetrahydro-amino-naphtalenyl- and aminoindan derivatives and pharmaceutical compositions comprising them |
| US5840979A (en) | 1997-07-14 | 1998-11-24 | University Of Saskatchewan | Aliphatic propargylamines as cellular rescue agents |
| PL353180A1 (en) | 1999-04-29 | 2003-11-03 | Merck Patent Gmbh | Glycine cleavage system inhibitors as potential antipsychotics |
| KR20040018394A (ko) * | 2001-07-04 | 2004-03-03 | 썬 파마슈티컬 인더스트리스 리미티드 | 위 정체 제어되는 약물 전달 계 |
| US20040076668A1 (en) | 2002-07-03 | 2004-04-22 | Pfizer Inc. | Controlled-release pharmaceutical formulations |
| WO2004045515A2 (en) * | 2002-11-15 | 2004-06-03 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
| CA2554959A1 (en) * | 2004-01-29 | 2005-08-11 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions |
| EP1778196A4 (en) * | 2004-07-26 | 2008-12-17 | Teva Pharma | PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE |
| AR055070A1 (es) * | 2005-06-29 | 2007-08-01 | Panacea Biotec Ltd | Una composicion farmaceutica de liberacion sostenida, proceso para la preparacion de dicha composicion, metodo para la utilizacion de la misma y su uso |
| WO2007016284A2 (en) * | 2005-07-28 | 2007-02-08 | Shire Llc | Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily |
| EP1909767A2 (en) * | 2005-07-28 | 2008-04-16 | Supernus Pharmaceuticals, Inc. | Modified release tablet formulations with enhanced mechanical properties |
| CN101032474B (zh) * | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
| CN101486655A (zh) | 2008-01-17 | 2009-07-22 | 美德（江西）生物科技有限公司 | 甲磺酸雷沙吉兰晶形及其制备方法 |
| NZ590291A (en) | 2008-06-06 | 2013-11-29 | Pharma Two B Ltd | Pharmaceutical compositions for treatment of parkinson's disease |
| EP2285214B1 (en) | 2008-06-10 | 2012-05-16 | Teva Pharmaceutical Industries Ltd. | Rasagiline soft gelatin capsules |
| AR074637A1 (es) * | 2008-07-18 | 2011-02-02 | Medichem Sa | Formas de sal de adicion acida de r-(+)-n-propargil-1-aminoindano (es decir , base de rasagilina), un compuesto de formula (1), procesos para prepararlos y aislarlos y usos de los mismos |
| EP2218444A3 (en) | 2009-01-23 | 2010-08-25 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
| KR101791715B1 (ko) * | 2010-02-03 | 2017-10-30 | 파마 투 비 엘티디 | 라사길린의 연장 방출 제형 및 그 용도 |
-
2011
- 2011-02-03 KR KR1020127023006A patent/KR101791715B1/ko active Active
- 2011-02-03 NZ NZ602111A patent/NZ602111A/en not_active IP Right Cessation
- 2011-02-03 LT LTEP11707489.8T patent/LT2531181T/lt unknown
- 2011-02-03 EP EP11707489.8A patent/EP2531181B1/en active Active
- 2011-02-03 DK DK11707489.8T patent/DK2531181T3/da active
- 2011-02-03 EP EP19159171.8A patent/EP3517103A1/en not_active Withdrawn
- 2011-02-03 US US13/577,099 patent/US9943489B2/en active Active
- 2011-02-03 SG SG2012057493A patent/SG183150A1/en unknown
- 2011-02-03 ES ES11707489T patent/ES2733133T3/es active Active
- 2011-02-03 PT PT11707489T patent/PT2531181T/pt unknown
- 2011-02-03 CA CA2789006A patent/CA2789006C/en active Active
- 2011-02-03 WO PCT/IL2011/000126 patent/WO2011095973A1/en not_active Ceased
- 2011-02-03 RU RU2016141314A patent/RU2734632C2/ru active
- 2011-02-03 RU RU2012136723A patent/RU2607595C2/ru active
- 2011-02-03 BR BR112012019374-0A patent/BR112012019374B1/pt active IP Right Grant
- 2011-02-03 TR TR2019/09277T patent/TR201909277T4/tr unknown
- 2011-02-03 RS RS20190810A patent/RS58988B1/sr unknown
- 2011-02-03 AU AU2011212068A patent/AU2011212068B2/en active Active
- 2011-02-03 PL PL11707489T patent/PL2531181T3/pl unknown
- 2011-02-03 MX MX2012009079A patent/MX354423B/es active IP Right Grant
- 2011-02-03 HU HUE11707489 patent/HUE044221T2/hu unknown
- 2011-02-03 JP JP2012551732A patent/JP6045347B2/ja active Active
- 2011-02-03 CN CN201180012590.4A patent/CN102791258B/zh active Active
-
2012
- 2012-08-02 IL IL221274A patent/IL221274A/en active IP Right Grant
- 2012-08-03 CL CL2012002175A patent/CL2012002175A1/es unknown
- 2012-08-28 ZA ZA2012/06462A patent/ZA201206462B/en unknown
-
2016
- 2016-09-26 JP JP2016186945A patent/JP6440662B2/ja active Active
-
2018
- 2018-11-20 JP JP2018216973A patent/JP6770564B2/ja active Active
-
2019
- 2019-07-03 CY CY20191100699T patent/CY1121781T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201909277T4 (tr) | Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları. | |
| ZA202202711B (en) | Sustained-release dosage forms of ruxolitinib | |
| SG10201810985XA (en) | Tofacitinib oral sustained release dosage forms | |
| MY165149A (en) | Use of binders for manufacturing storage stable formulations | |
| UA104869C2 (uk) | Фармацевтичні композиції, що містять ліганди рецептора дофаміну | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| MY157673A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| MX2015001917A (es) | Composiciones farmaceuticas de memantina. | |
| ATE487720T1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer | |
| PH12012502083A1 (en) | Manufacturing of active-free granules and tablets comprising the same | |
| CY1113759T1 (el) | Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2 | |
| PH12015500823A1 (en) | Modified release formulations for oprozomib | |
| EA201171087A1 (ru) | СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ | |
| MA32841B1 (fr) | Composés de cycloundeca depsipeptides et leur utilisation comme médicament | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| MX2012012410A (es) | Agente terapeutico y agente preventivo para enfermedad de alzheimer. | |
| MX2021014093A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| EA201390619A1 (ru) | 3-замещенные 6-(пиридинилметокси)пирролопиридиновые соединения | |
| MX2008011017A (es) | Compuestos de receptor sigma. | |
| PH12019501070A1 (en) | Sustained-release dosage forms of ruxolitinib | |
| UA101370C2 (ru) | Пероральные составы, которые содержат аналоги цитидина, и способы их использования | |
| TH138424A (th) | สูตรผสมผงแห้งที่ประกอบรวมด้วยยาต้านมัสคารินิก | |
| TH171493A (th) | สูตรผสมทางเภสัชกรรม |